-
公开(公告)号：KR101351121B1
公开(公告)日：2014-01-14
申请号：KR1020110014438
申请日：2011-02-18
Applicant: 가톨릭대학교 산학협력단
Abstract: 본 발명은 IL-27을 유효성분으로 포함하는 면역거부질환의 예방 또는 치료용 조성물에 관한 것으로서, 보다 구체적으로 본 발명의 IL-27 단백질은 세포 또는 조직 이식 후 면역 거부 반응과 관련된 질환을 보이는 동물에게 투여하였을 때, 이식된 세포 또는 조직이 생착된 후 숙주에 대한 거부반응을 억제시킴으로써 면역거부질환을 완화시키는 효과를 갖는다. 따라서 상기와 같은 효과를 갖는 IL-27 단백질 및 IL-27 단백질을 암호화하는 핵산을 유효성분으로 포함하는 본 발명의 조성물은 면역 거부 반응 관련 질환의 예방 또는 치료에 유용하게 사용될 수 있는 특징이 있다.
-
公开(公告)号：KR1020120095046A
公开(公告)日：2012-08-28
申请号：KR1020110014438
申请日：2011-02-18
Applicant: 가톨릭대학교 산학협력단
CPC classification number: A61K38/20 , A61K48/005 , Y10S424/81
Abstract: PURPOSE: A composition for preventing or treating immunological rejection diseases including IL-27 is provided to alleviate the immunological rejection disease by suppressing rejection towards the host after the transplanted cell or organ is engrafted. CONSTITUTION: A composition for preventing or treating immunological rejection diseases includes IL-27 as an active component. The IL-27 has amino acid sequence described in the sequence number 1(SEQ ID NO:1). The composition for preventing or treating immunological rejection diseases includes a vector containing polynucleotide which codes the IL-27 as an active ingredient. The polynucleotide has the base sequence described in the sequence number 2. The immunological rejection disease is graft-versus-host disease.
Abstract translation: 目的：提供一种用于预防或治疗免疫排斥疾病（包括IL-27）的组合物，用于通过在移植的细胞或器官移植后抑制对宿主的排斥来减轻免疫排斥疾病。 构成：用于预防或治疗免疫排斥疾病的组合物包括IL-27作为活性成分。 IL-27具有序列号1（SEQ ID NO：1）中描述的氨基酸序列。 用于预防或治疗免疫排斥疾病的组合物包括编码IL-27作为活性成分的含有多核苷酸的载体。 多核苷酸具有序列号2中描述的碱基序列。免疫排斥疾病是移植物抗宿主病。
-
公开(公告)号：KR1020120095063A
公开(公告)日：2012-08-28
申请号：KR1020110014466
申请日：2011-02-18
Applicant: 가톨릭대학교 산학협력단
CPC classification number: A61K38/1758 , A61K38/20 , C07K14/4713 , C07K14/4746
Abstract: PURPOSE: A composition for preventing or treating immunization diseases including p53 induced by il-27 is provided to increase expression of p53 by getting stimulation of the IL-27 and to enhance arthritis in animal models according to the expression of p53. CONSTITUTION: A composition for preventing or treating immunization diseases includes p53. The p53 has amino acid sequence described in the sequence number 1(SEQ ID NO:1) or 2. The composition additionally includes the interleukin-27(IL-27). The interleukin-27(IL-27) multiplies the activities of the gene expression of p53 or the p53 protein. The composition for preventing or treating immunization diseases includes a promoter and a vector containing polynucleotide which codes the p53. The polynucleotide has the base sequence described in the sequence number 3 or 4.
Abstract translation: 目的：提供一种用于预防或治疗由il-27诱导的免疫疾病包括p53的组合物，以通过刺激IL-27并根据p53的表达增强动物模型中的关节炎来增加p53的表达。 构成：用于预防或治疗免疫疾病的组合物包括p53。 p53具有序列号1（SEQ ID NO：1）或2所述的氨基酸序列。该组合物另外包括白细胞介素-27（IL-27）。 白介素-27（IL-27）将p53或p53蛋白的基因表达的活性相乘。 用于预防或治疗免疫疾病的组合物包括编码p53的启动子和含有多核苷酸的载体。 多核苷酸具有序列号3或4中描述的碱基序列。
-
-
Search Results
3
records
(took 0.062 seconds)
